100% virological response and adherence in HCV genotype 1 liver cirrhosis treated with 3D regimen in a Romanian real-life cohort
AASLD LiverLearning®, Liliana Simona Gheorghe, 144896
Symptom Clusters Generated using Factorial Analysis of PROMIS tools Independently Predict Hospitalizations and Re-hospitalizations in Cirrhosis
AASLD LiverLearning®, Jasmohan S. Bajaj, 144653
Lack of compliance to hepatocellular carcinoma (HCC) screening guidelines in hepatitis B (HBV) or C (HCV) virus co-infected HIV patients with cirrhosis
AASLD LiverLearning®, Sophie Willemse, 144654
Failure with DDA regimens in a high volume treatment center under real life conditions
AASLD LiverLearning®, Jörg Petersen, 144911
Sustained virologic response (SVR) in patients taking ledipasvir-sofosbuvir (LDV/SOF) and a proton pump inhibitor (PPI) in the treatment of chronic hepatitis C virus (HCV)
AASLD LiverLearning®, Jordan Mangum, 144912
The role of IL-27 in predicting spontaneous HBeAg seroconversion in chronic hepatitis B infection
AASLD LiverLearning®, Lung Yi Mak, 144669
Patients with HDV infection and advanced fibrosis/cirrhosis present a high but predictable risk of developing hepatocellular carcinoma
AASLD LiverLearning®, GIOVANNI B. GAETA, 144670
Dengue fever in cirrhosis patients can lead to acute hepatic decompensation & increased mortality
AASLD LiverLearning®, Anand Kulkarni, 144927
Trends in Hospitalization for a Population-Based Cohort with Cirrhosis and Multiple Chronic Conditions: time to change the definition of decompensated cirrhosis?
AASLD LiverLearning®, Sumeet Asrani, 144928
US Asian HBV Patients Have Liver Steatosis and Metabolic Syndrome at Lower BMI than non Asians
AASLD LiverLearning®, William Clarke, 144685
Survival following hepatocellular carcinoma among people with HBV or HCV in New South Wales, Australia between 2000 and 2014
AASLD LiverLearning®, Reem Waziry, 144686
The combined of Urine Neutrophil Gelatinase-associated Lipocalin and the CLIF-SOFA score in prediction of mortality of patients with acute-on-chronic liver failure
AASLD LiverLearning®, Tongluk Teerasarntipan, 144943
Thrombocytopenia is frequent finding in cirrhotic patients treated with piperacillin-tazobactan and is associated with increased morbidity and mortality
AASLD LiverLearning®, Gustavo Pereira, 144944
Prediction of hepatitis B virus-related liver cancer incidence and recurrence after anticancer therapy by hybrid evaluation of serum WFA(+)-M2BP and hepatitis B core-related antigen
AASLD LiverLearning®, Kazunori Kawaguchi, 144701
IL-22 Gene Haplotype Polymorphisms Are Associated with the Risk of Liver Cirrhosis in Patients with Hepatitis B Virus
AASLD LiverLearning®, Yanhang Gao, 144702
Can Renalase Disfunction Influence Adrenergic Activation in Liver Cirrhosis?
AASLD LiverLearning®, Giovanni Sansoe', 144959
Adaptive Bayesian Analysis Personal Reference Ranges of Serum Creatinine and Urea for the Prediction of Acute Kidney Injury in Cirrhosis.
AASLD LiverLearning®, Kavish Patidar, 144960
Serum microRNA-122 as well as WFA(+)-M2BP is a good predictor of liver fibrosis in chronic hepatitis B infection
AASLD LiverLearning®, Masato Nakamura, 144718
Clinical outcomes after spontaneous and nucleos(t)ide analogues (NUCs)-treated hepatitis B surface antigen(HBsAg) seroclearance in chronic HBV infection are favourable
AASLD LiverLearning®, Xiang-Yong Li, 144719
Deoxycholylglycine (DCG), a Conjugated Secondary Bile Acid (BA), Reduces Myogenic Tone by reducing Ca2+ Sensitivity via Rho kinase pathway
AASLD LiverLearning®, Sandeep Khurana, 144975
Cystatin C is better than creatinine for predicting prognosis in cirrhotic patients with sarcopenia
AASLD LiverLearning®, Han ah Lee, 144976
Predictive role of serum HBsAg and HBcrAg levels in patients with HBeAg-negative chronic hepatitis B treated with pegylated interferon-based therapy
AASLD LiverLearning®, Pisit Tangkijvanich, 144734
Circulating microparticles carry apoptosis markers CK-18 and caspase-3/7 which are reduced by treatment with Emricasan in subjects with chronic liver diseases
AASLD LiverLearning®, Akiko Eguchi, 144990
No Resistance to Tenofovir Alafenamide Detected Through 48 Weeks of Treatment in Patients with Chronic Hepatitis B
AASLD LiverLearning®, Henry LY Chan, 144735
Emricasan (IDN-6556) Orally for 6 Months in Patients with Non-alcoholic Steatohepatitis (NASH) Cirrhosis Decreases the Progression of MELD score and Improves Liver Function
AASLD LiverLearning®, Catherine Frenette, 144991
Aquaretic effects of α2A adrenergic receptor agonists (sympatholytic agents) vs. vasopressin V2 receptor antagonists in Experimental Ascitic Cirrhosis.
AASLD LiverLearning®, Giovanni Sansoe', 144992
Genotype Specific Differences In Magnitude Of HBsAg Reduction During TDF or tenofovir alfenamide (TAF) Therapy In CHB Patients
AASLD LiverLearning®, Patrick Marcellin, 144750
HBV genotype is associated with early (week 12) virologic response during TDF or TAF therapy in patients with chronic hepatitis B
AASLD LiverLearning®, Subrat Acharya, 144751
A real-world experience in baseline predictors of virological response to Peginterferon Alfa-2a in patients with HBeAg-negative chronic hepatitis B
AASLD LiverLearning®, Yi-Cheng Chen, 144766
The Prenylation Inhibitor Lonafarnib Can Induce Post-Treatment Alt Flares With Viral Clearance In Patients With Chronic Delta Hepatitis
AASLD LiverLearning®, Cihan Yurdaydin, 144767
Comparison of Renal safety of Tenofovir (TDF) and Entecavir (ETV) in Patients with Chronic Hepatitis B (CHB): A Systematic Review with Meta-Analysis
AASLD LiverLearning®, Hyo Young Lee, 144783
Serum HBsAg kinetics in relation to hepatitis flare during first 6 months of direct antiviral therapy
AASLD LiverLearning®, Rachel Wen-Juei Jeng, 144784
Prevalence and Predictors of Fragility Fracture in Corticosteroid-treated Patients with Autoimmune Hepatitis (AIH)
AASLD LiverLearning®, Laura Harrison, 144541
Mycophenolate Mofetil in Autoimmune Hepatitis Patients not Responsive or Intolerant to Standard Therapy: the Australian TAPESTRY study
AASLD LiverLearning®, Alessia Gazzola, 144542
Treatment efficacy of switching to tenofovir strategy over continued entecavir therapy in chronic hepatitis B patients with partial virologic response to entecavir
AASLD LiverLearning®, Jun Seop Lee, 144799
Evolution and Predictive Role of Basal Core Promoter and Precore Mutants in Genotype B or C Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Undergoing Peginterferon Therapy
AASLD LiverLearning®, Cheng Yuan Peng, 144800
IL-4 and IL-13 regulate liver fibrosis through M2 macrophages, but not Th2 T cells or hepatocytes
AASLD LiverLearning®, Shih-yen Weng, 144557
Inhibition of the substance P/neurokinin-1 receptor (NK-1R) axis decreases liver fibrosis in the Mdr2-/- mouse model of primary sclerosing cholangitis (PSC) through changes in senescence in cholangiocytes and hepatic stellate cells.
AASLD LiverLearning®, Guo-Ying Wang, 144558
Treatment of chronic HCV Infection with direct antiviral agents (DAA) results in rapid regression of transient elastography (Fibroscan®) and validated fibrosis markers FIB-4 and APRI
AASLD LiverLearning®, Jacqueline Bachofner, 144815
Favorable efficacy of combination therapy with direct-acting antivirals to elderly aged 70 and older with HCV genotype 1
AASLD LiverLearning®, Norio Akuta, 144816
Mice with genetic deletion of ecto-nucleoside triphosphate diphosphohydrolase 3 (NTPDase3) are protected from development of both biliary and parenchymal-type liver fibrosis
AASLD LiverLearning®, Linda Feldbrugge, 144573
Systems biology approach to identify processes and early markers for fibrosis in metabolically-induced NASH in mice
AASLD LiverLearning®, Arianne van Koppen, 144574
Interferon, Ribavirin or Direct Antiviral Agent-Based Regimens for Treatment of Hepatitis C Among Patient with Porphyria Cutanea Tarda
AASLD LiverLearning®, Krishna Venkata, 144831
High Effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection in Elderly Patients in a National Healthcare System
AASLD LiverLearning®, George Ioannou, 144832
Th2-polarization of CD4+ T-cells is locally induced and drives liver fibrogenesis
AASLD LiverLearning®, Johanna Reissing, 144589
PlGF silencing ameliorates hepatic angiogenesis in mice with liver fibrosis induced by carbon tetrachloride
AASLD LiverLearning®, Chuantao Tu, 144590
Protease inhibitor and non-structural protein 5A inhibitor regimen can improve the health-related quality of life (HRQOL) in Japanese patients with genotype 1b hepatitis C virus
AASLD LiverLearning®, ikeda hiroki, 144847
LNCRNA H19 Is Increased In Hepatocellular Carcinoma With Underlying Hcv-Related Cirrhosis
AASLD LiverLearning®, Marta García-Valdecasas, 144848
Spleen stiffness is superior to liver stiffness for predicting esophageal varices in chronic liver disease: a meta-analysis
AASLD LiverLearning®, Xiaowen Ma, 144605
Psoas Muscle Density Improves Survival Predictability Following TIPS
AASLD LiverLearning®, Mohamed Shoreibah, 144606
Comorbidities, Co-medication and Potential Drug to Drug Interactions in Chronic Hepatitis C Patients (CHC): Implications for Adequate HCV Treatment Selection - Data from a large transversal study in Germany and France
AASLD LiverLearning®, Stefan Christensen, 144863
Maximizing access to HCV treatment with direct-acting antiviral agents for uninsured patients in the United States.
AASLD LiverLearning®, Andres Carrion, 144864
Impact of hepatitis C virus reflex testing on the hepatitis C care continuum among baby boomers in a urban health system
AASLD LiverLearning®, Aparna Goel, 144621
The association between alanine aminotransferase and renal function in the Japan population: the Yamagata (Takahata) study.
AASLD LiverLearning®, Hiroaki Haga, 144622
Real-world efficacy and safety of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with HCV genotype 1 and 4 infection, final results of the AMBER study
AASLD LiverLearning®, Robert Flisiak, 144879
OMV/PTV/RTV +/- RBV in Genotype 4, Hard-To-Treat cohorts: real Life Data From Qatar
AASLD LiverLearning®, Moutaz Derbala, 144880
Improving Age-Based Hepatitis C Screening at a Veterans Affairs Primary Care Clinic
AASLD LiverLearning®, Jessica Rubin, 144637
Post-Discharge Mortality in a National Cohort of Veterans Affairs Patients with Cirrhosis
AASLD LiverLearning®, Jejo Koola, 144638
Sofosbuvir/Ledipasvir without Ribavirin is effective in the treatment of recurrent hepatitis C infection post liver transplant
AASLD LiverLearning®, Mohamed Shoreibah, 144895
Module 1: Anatomy and Physiology of the Liver
AASLD LiverLearning®, Tamar Taddei, 119131
Management of Hepatic Encephalopathy
AASLD LiverLearning®, Jasmohan Bajaj, 154717
Surgery Risk Assessment in the Cirrhotic Patient
AASLD LiverLearning®, Patrick Northup, 154716
Update in Wilson Disease
AASLD LiverLearning®, Eve Roberts, 154715
Pegylated interferon alfa-2a (40KD) is efficacious and safe in treatment of HBeAg-positive children with chronic hepatitis B: Peg-B-Active study
AASLD LiverLearning®, Stefan Wirth, 155355
Hepatology Associates Course
AASLD LiverLearning®, Session Speakers, 155769
HIV, HBV, HCV Coinfections
AASLD LiverLearning®, Douglas Dieterich, 154676
Approach to the Patient with Iron Overload
AASLD LiverLearning®, Kris Kowdley, 154675
Adult Living Donor Liver Transplant: Donor and Recipient Considerations
AASLD LiverLearning®, Rebecca Duke, 154674
Awarded Poster Presentation
AASLD LiverLearning®, Anna Hefner, 154673
iPSC and Disease Modeling in the Liver
AASLD LiverLearning®, Ludovic Vallier, 154691
The Impact of Cirrhotic PVT on Liver Transplant: A Medical Perspective
AASLD LiverLearning®, Nicolas Intagliata, 154701
Complications of Cholestatic Liver Diseases
AASLD LiverLearning®, Cynthia Levy, 154672
iPSCs and Correction of A1AT Deficiency
AASLD LiverLearning®, Andrew Wilson, 154690
Cholangiocytes From iPSC
AASLD LiverLearning®, Romina Fiorotto, 155708
Treatment of PVT in Cirrhosis: Who, When and How
AASLD LiverLearning®, Juan Carlos Garcia-Pagan, 154700
Etiology of Liver Disease: Does it Make a Clinical Difference?
AASLD LiverLearning®, Jordi Bruix, 154712
Hepatocytes From iPSC
AASLD LiverLearning®, Holger Willenbring, 154688
Diagnosis and Natural History of PVT In Cirrhosis
AASLD LiverLearning®, Dominique Valla, 154699
Statins and Metformin as Chemoprevention for HCC
AASLD LiverLearning®, Lewis Roberts, 154711
Panel Discussion
AASLD LiverLearning®, Session Speakers, 155768
Future Landscape With HCV Therapy
AASLD LiverLearning®, Fred Poordad, 154669
Session II: Epidemiology and Clinical Insights
AASLD LiverLearning®, Gregory Gores, 154709
Liver Transplantation for NASH Associated HCC
AASLD LiverLearning®, Kimberly Ann Brown, 154710
Cirrhosis – Beyond Portal Hypertension
AASLD LiverLearning®, Lucy Mathew, 154668
Engineering of the Liver via iPSC
AASLD LiverLearning®, Takanori Takebe, 154685
Does Prophylactic Anticoagulation Alter the Course of Cirrhosis? Lessons from Prophylactic Trials
AASLD LiverLearning®, ERICA VILLA, 154698
Natural History: The Magnitude of the Problem from Hepatology Clinic Perspective
AASLD LiverLearning®, Augusto Villanueva, 154708
Parenchymal Extinction in 2016: What is the Human Evidence?
AASLD LiverLearning®, Ian R. Wanless, 154697
Management of Metabolic Syndrome and NASH
AASLD LiverLearning®, Rohit Loomba, 154667
Induced Pluripotent Stem Cells in the Future of Gastroenterology/Hepatology
AASLD LiverLearning®, Stephen Duncan, 154684
Diabetes Associated HCC: The Molecular Profile
AASLD LiverLearning®, Jessica Zucman-Rossi, 154707
Coagulation, Thrombin, Fibrosis and Inflammatory Pathways in the Liver
AASLD LiverLearning®, James Luyendyk, 154696
NAFLD Promotes HCC by Causing CD4(+)T Cell Depletion
AASLD LiverLearning®, Tim Greten, 154706
Developmental Biology: The Foundation for Gastrointestinal Tissue Engineering
AASLD LiverLearning®, James Wells, 154681
Hepatology Associates Course: Session I
AASLD LiverLearning®, Lisa Richards, 154664
Managing Alcoholic Hepatitis
AASLD LiverLearning®, Vijay Shah, 154666
Cirrhosis as a Prothrombotic State: Overview and Update
AASLD LiverLearning®, Ton Lisman, 154695
Restoration of bile acid homeostasis improves alcoholic liver disease in mice
AASLD LiverLearning®, Phillipp Hartmann, 144092
PNPLA3 G/G genotype doubles the mortality risk of patients with portal hypertension due to fatty liver disease
AASLD LiverLearning®, Mattias Mandorfer, 144108
Excess Adiposity in Alcoholic Hepatitis Increases Mortality and Morbidity
AASLD LiverLearning®, Richard Parker, 144124